

POLAND

Recent and planned developments in pharmaceutical policies 2015

Pre-launch activities: horizon scanning and forecasting

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<p>Polish MoH tries to initiate international discussion about fair pricing.</p> <p>e.g. age-related macular degeneration medicines used to treat the 'wet' form of amd:</p> <p>ranibizumab (lucentis)</p> <p>aflibercept (eylea) - registered in this indication</p> <p>appx. 3 x more in EUR/ 1 fiol.</p> <p>vs</p> <p>bevacizumab (avastin - the cancer medicine) used off-label appx. 345 EUR/1fiol.</p>	<p>No changes</p>
Other changes		
<p>Until 1st May 2016 we plan to implement e-application for management of the reimbursement list.</p> <p>Until 1st January 2017 we plan to implement monitoring system for medicinal products (dedicated to identifiably deficiencies of medicinal products).</p>		
S P E C I A L T O P I C	Pre-launch pharmaceutical policies: Horizon scanning and forecasts	
<p>In PL we work under the scope of the law that regulate the conduction of clinical trials. We are going to carry out non-commercial clinical trials.</p>		